Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It

Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance that easily beat the recovering S&P 500's (SNPINDEX: ^GSPC) 1.1% gain.The story was different with Hims & Hers Health (NYSE: HIMS), which earlier this year had stepped into a key Novo Nordisk product segment. That stock rose on Wednesday, but only by 1%.Before market open, Novo Nordisk announced the launch of its NovoCare Pharmacy, a direct-to-patient delivery service for its best-selling Wegovy weight loss drug. All four dose strengths of Wegovy are offered with the service, at a reduced cost of $499 monthly. The service targets uninsured patients, in addition to people with insurance who lack coverage for obesity treatments.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool